Modality
Vaccine
MOA
PRMT5i
Target
BCL-2
Pathway
NF-κB
CRCRB
Development Pipeline
Preclinical
~Jan 2015
→ ~Apr 2016
Phase 1
~Jul 2016
→ ~Oct 2017
Phase 2
~Jan 2018
→ ~Apr 2019
Phase 3
~Jul 2019
→ ~Oct 2020
NDA/BLA
~Jan 2021
→ ~Apr 2022
Approved
Jul 2022
→ Aug 2031
ApprovedCurrent
NCT07098483
48 pts·RB
2022-08→2031-08·Terminated
NCT03802615
1,542 pts·CRC
2022-07→2026-06·Completed
NCT06769244
904 pts·CRC
2025-12→2028-01·Recruiting
2,494 total pts2 indications
CompletedCurrentUpcoming
Catalysts (4)
2025-11-135mo agoConference· CRC
2026-06-042mo awayPh3 Readout· CRC
2028-01-171.8y awayPh3 Readout· CRC
2031-08-065.3y awayPh3 Readout· RB
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Complet…
Approved
Termina…
Approved
Recruit…
Catalysts
Conference
2025-11-13 · 5mo ago
CRC
Ph3 Readout
2026-06-04 · 2mo away
CRC
Ph3 Readout
2028-01-17 · 1.8y away
CRC
Ph3 Readout
2031-08-06 · 5.3y away
RB
RecruitingCompletedTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07098483 | Approved | RB | Terminated | 48 | MRD |
| NCT03802615 | Approved | CRC | Completed | 1542 | UPCR |
| NCT06769244 | Approved | CRC | Recruiting | 904 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 |